해부 병리학 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2024-2032년)

The Global Anatomic Pathology Market, valued at around USD 36.7 billion in 2023, is projected to grow at a CAGR of 7.8% from 2024 to 2032. Anatomic pathology, a specialized branch of pathology, focuses on diagnosing diseases by examining surgical specimens, tissues, and organs. Utilizing techniques like histopathology, cytopathology, and autopsy pathology, anatomic pathologists analyze samples at a cellular level, uncovering structural and functional changes caused by disease processes.

The growing prevalence of diseases, particularly cancer, drives significant demand for anatomic pathology services. With an increasing disease burden worldwide, the need for precise diagnostic tools has surged. Techniques like histopathology and cytopathology are critical for accurate disease detection and management, fueling market growth. Furthermore, the expanding use of biomarkers, advancements in pathology equipment, and the rise in clinical trials are all enhancing diagnostic precision and reliability. Technologies like digital pathology further support the efficiency and accuracy of diagnoses, contributing to the sector's growth.

Market segments based on products and services include instruments, consumables, and services. The consumables segment, which generated USD 19.2 billion in revenue in 2023, led the market and is anticipated to maintain robust growth. High-quality consumables, such as precision slides and reagents, are essential for improving diagnostic accuracy and standardization across labs. Ready-to-use consumables enhance workflow efficiency, minimizing preparation time and improving lab productivity by enabling technicians to focus on specimen analysis.

By application, the market is divided into disease diagnostics and research, with disease diagnostics, particularly cancer diagnostics, holding a substantial market share in 2023. Anatomic pathology enables detailed tissue and cell analysis, providing valuable insights into disease morphology, which aids in accurate diagnosis. Integration with molecular testing techniques, like genomics and proteomics, further enhances personalized medicine by aligning diagnostic findings with genetic and biomarker data.

The end-use segment of hospitals held a 55.4% share in 2023 and is poised for substantial growth. Hospitals benefit from access to a broad range of diagnostic tools, allowing for a comprehensive approach to patient care. Advanced molecular testing, combined with anatomic pathology, enables hospitals to offer personalized treatments, especially for oncology, thus enhancing treatment outcomes and patient satisfaction.

In North America, the U.S. leads the anatomic pathology market due to high disease prevalence and a well-established healthcare infrastructure. Advanced diagnostic technologies, including digital pathology and AI-driven tools, are widely adopted, boosting diagnostic accuracy and enhancing overall patient care.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of cancer and other target diseases worldwide
    • 3.2.1.2 Growing adoption of biomarkers
    • 3.2.1.3 Increasing number of clinical trials pertaining to cancer drugs
    • 3.2.1.4 Increasing technological advancements of pathology equipment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of equipment
    • 3.2.2.2 Availability of refurbished anatomic pathology systems
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product and Service, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
  • 5.2.1 Microtomes
  • 5.2.2 Cell processors
  • 5.2.3 Tissue processing systems
  • 5.2.4 Slide staining systems
  • 5.2.5 Embedding systems
  • 5.2.6 Coverslippers
  • 5.2.7 Other instruments
• 5.3 Consumables
  • 5.3.1 Antibodies
    • 5.3.1.1 Primary antibodies
    • 5.3.1.2 Secondary antibodies
  • 5.3.2 Kits and reagents
    • 5.3.2.1 Stains and solvents
    • 5.3.2.2 Fixatives
    • 5.3.2.3 Other kits and reagents
  • 5.3.3 Probes
  • 5.3.4 Other consumables
• 5.4 Services
  • 5.4.1 Histopathology
  • 5.4.2 Cytopathology

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Diseases diagnostics
  • 6.2.1 Cancer
    • 6.2.1.1 Breast cancer
    • 6.2.1.2 Gastrointestinal cancer
    • 6.2.1.3 Lung cancer
    • 6.2.1.4 Prostate cancer
    • 6.2.1.5 Other cancer types
  • 6.2.2 Other diseases
• 6.3 Research

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic centers
• 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Supply-side
  • 9.1.1 Agilent Technologies
  • 9.1.2 Becton, Dickinson and Company
  • 9.1.3 Cardinal Health
  • 9.1.4 Danaher Corporation
  • 9.1.5 F. Hoffmann-La Roche
  • 9.1.6 Merck
  • 9.1.7 Thermo Fisher Scientific
• 9.2 Demand-side (Laboratories)
  • 9.2.1 Ampath Laboratories
  • 9.2.2 Al Borg Medical Laboratories
  • 9.2.3 Biolab
  • 9.2.4 Eurofins Scientific
  • 9.2.5 Laboratoires Reunis
  • 9.2.6 Lifebrain Group
  • 9.2.7 Lancet Laboratories
  • 9.2.8 Medsol Diagnostics
  • 9.2.9 Synlab Group
  • 9.2.10 Unilabs